Austco Healthcare Limited (ASX:AHC)
Australia flag Australia · Delayed Price · Currency is AUD
0.2600
0.00 (0.00%)
Nov 17, 2026, 11:31 AM AEDT
← View all transcripts

Bell Potter Healthcare Conference

Nov 16, 2026

Summary

FY 2026 revenue reached AUD 94.2m (+~16%) and EBITDA AUD 14.9m (+14%); software maintenance revenue rose 19% to AUD 11.4m. RTM and CareTech are expected to broaden recurring software and care workflows, while strong hospital demand is tempered by project timing delays.

Speaker 1

Welcome back. We are pleased to welcome Clayton Astles, CEO of Austco Healthcare, present to us today. Austco Healthcare is an international healthcare communications and clinical workflow management solutions provider. Austco manufactures sophisticated nurse call systems, enterprise reporting tools, and analytics for the hospital and aged care sectors. The company supports healthcare facilities through its global reseller network, which includes growing markets in health, aged care, and acute care. Austco services an industry growing at double digits, reflecting the aging demographics of its key markets. More recently, Austco has finally passed the AUD 100 million revenue milestone, so that is a really important achievement for the company. Clayton will speak for about 15 minutes, working through a slide deck, followed by 10 minutes for Q&A. Welcome, Clayton.

Clayton Astles
CEO, Austco Healthcare

Thank you, Martin, and thank you to Bell Potter for inviting us. Good morning, everyone. I am Clayton Astles, Chief Executive Officer of Austco Healthcare. Today, I would like to give you an overview of Austco and our track record, our growth strategy, and what is next for the business. Let us start with why Austco. Put simply, when a patient needs assistance, our care communication systems make sure the right caregivers are alerted, and we are providing tools to improve patient outcomes and staff efficiency. Those are very important objectives for our business and for our product roadmap. These are just some of the reasons why an investment in Austco is a good one. One, a proven, growing global business. Since FY 2023, revenue is up 124% and EBITDA is up more than 300%. We serve thousands of facilities in more than 60 countries around the world.

Two, a product suite built for growing demand for better care and staff efficiencies. Populations are aging, and clinical staff are under a lot of pressure, so hospitals need technology that takes some of the workload off caregivers. RTM and CareTech, once those acquisitions are completed, give us more ways to help patients and caregivers. Three, financial strength. We have more than AUD 51 million in contracted revenue still to deliver, 25% of that in software maintenance revenues, and we are funding RTM and CareTech acquisitions from cash and a new AUD 12 million bank facility with no new shares issued. Here is what that looks like in the numbers. FY 2026 was a record year for Austco. Revenue was up about 16% to AUD 94.2 million, and EBITDA up 14% to AUD 14.9 million.

Net profit after tax was AUD 9 million, up about 52%, and gross margins improved by 140 basis points to 53.4%. The three-year view is the real story. Revenue has gone from AUD 42 million -AUD 94 million, and EBITDA has gone from AUD 3.6 million -AUD 14.9 million, with margin improving from 8.5%- 15.8%. That is EBITDA margin. Top left, revenue by region. Most of the growth came from Australia and New Zealand, where we bought our partners in-house. North America also saw strong growth. Over three years, the businesses generated AUD 37 million of operating cash after acquisitions and earnout payments, plus continued investment in R&D. Cash went from AUD 4.7 million -AUD 16.3 million. Recurring revenue is building. Software maintenance revenues are up 19% to AUD 11.4 million. We have our acquisitions built in the model. Our acquisitions have moved through two phases.

First, our own resellers, Teknocorp, Amentco, G&S Technologies, and MCS. Bringing them in-house allows us to have a direct relationship with our customers and gives us national coverage across Australia and New Zealand. We are now adding technology to our product portfolio with the acquisitions of RTM and CareTech. CareTech gives us a cost-effective solution for aged care and smaller hospitals, whereas RTM gives us proactive system health monitoring installed. It is currently installed at more than 600 facilities in Australia. In FY 2026, RTM generated approximately AUD 15.6 million of revenue and AUD 2.2 million of EBITDA. Completion of both is expected on or around December 1st, 2026, subject to conditions. Let us look at how it all fits together on one platform. Four levels, one Austco platform, starting at the bedside.

At the bedside, call points, in-room devices, and real-time location tell staff who is calling and where. CareTech adds a lower-cost system for aged care and smaller hospitals. In the ward, patient status boards and Pulse Mobile, our mobile app, route the call to the right clinician on their device at the right time. Across the facility, Tacera, our platform, manages alarms and call routing, and RTM's more than 300 system interfaces will connect to the platform of the other hospital systems, including real-time location, access control, fire, and security. At the command center at the top, enterprise reporting across every site, plus RTM's proactive system health monitoring. We intend to offer RTM Cloud, the platform, to thousands of customers around the world. Encompass Health, the largest inpatient rehabilitation network in the United States, has standardized on our Pulse Mobile for its new hospitals. That is our model in action.

Win the healthcare system, then grow with it facility by facility. Connecting every system also gives us something else, data. That is where AI comes in. We are building an intelligence into the platform our customers already use, not bolting it on as a separate product. What is live today is operational analytics and Pulse Insights, response times, staff adequacy, and compliance readiness. On the roadmap, predictive clinical intelligence such as fall risk and early warning of deterioration. Intelligent workflow, routing staff on acuity, workload, and proximity. With RTM, predictive system health monitoring, flagging issues before any downtime. All of these together make the platform stickier and help drive recurring software revenue growth. Finally, looking at some of our strategic priorities. Four priorities: expanding recurring revenue, software maintenance, up 19% to AUD 11.4 million, anchored by our 10-year Jurong Health maintenance agreement in Singapore, which we announced recently.

Enhance our margin profile, gross margin up 140 basis points to 53.4% from supply chain efficiencies delivered through integration. Deepen our market presence, flagship reference sites in every region, including Albert Einstein Hospital in Latin America, Jurong Hospital in Singapore. We manage our risks, project timing, tariffs, component supply, and currency. About 80% of our contracted revenue is in foreign currencies, and we dual source key components wherever we can. Underpinning all of this are our people. We are building a leadership team and a business that scales, and we look forward to welcoming the RTM and CareTech teams on completion. What is next? Completing RTM and CareTech, integrating those businesses, and taking RTM Cloud to our international customers. That is Austco Healthcare, a proven model, a platform customers standardize on, and innovative products to help patients and caregivers. Thank you, Martin.

Speaker 1

Thanks for that overview, Clayton. Really appreciate that. There is a strategy to increase software revenue as a percentage of overall sales. What medium-term target have you set for yourselves, if you can share that with us, and what margin are you earning on that software revenue at the moment?

Clayton Astles
CEO, Austco Healthcare

Yeah, we haven't published a specific target, but with the acquisition of RTM, we expect growth in software maintenance revenues across the group globally once that business is fully integrated. We are planning to roll out that platform immediately, which generates recurring revenues. We are pushing it in two directions organically. Every solution we install will include a support and maintenance agreement, and we have changed how our sales teams are compensated as well, Martin, across the group. So we are incentivizing them to sell more of those software and recurring revenue solutions. RTM is our first software acquisition, and every RTM installation creates ongoing license, maintenance, and support revenues, and we will be taking that to our existing customer base around the world.

Speaker 1

In the presentation slides, you mentioned there that your UCR or backlog revenue of AUD 50-odd million, and about 25% of that, I think, if I read it correctly, is software maintenance revenue. Last year, you had around 11%, 12% of software revenues relative to overall sales. So, can we deduce from the UCR that software and maintenance revenues might actually head up to that 25% mark?

Clayton Astles
CEO, Austco Healthcare

Yeah, you can draw some conclusions. It also, what that UCR number doesn't tell you when it is going to be recognized. Some of them are larger hospitals that are recognized over a longer period of time. It also doesn't factor in CareTech and RTM and some of the other services they do provide, labor and that sort of thing. But it is a good indicator that it is growing. So, while I wouldn't take that number as to say that that is what the number will be, it is a sign that the software component of our contracts is continuing to grow.

Speaker 1

Right. We have a question from the audience. It asks, what prevents larger healthcare providers from replicating what you've achieved? I was just wondering what your thoughts on that are.

Clayton Astles
CEO, Austco Healthcare

Yeah. The barrier of entry is quite high. It is a very regulated industry as well. For example, in the United States, we are registered with the Food and Drug Administration, the FDA, and we are audited frequently by the FDA. You cannot operate in the United States without having a quality management system that meets FDA requirements and passing those audits. We have other regulatory standards around the world. Not only that, it takes many years and talent inside the organization to develop these solutions. The barriers of entry are quite high, and we are happy with how we are placed competitively.

Speaker 1

Right. Okay. I think there have been six acquisitions in the last three years. I am wondering how many more you might make in the next three years, and how many targets there are in your pipeline. Will they enable you to reach your aspirational revenue target of AUD 250 million by then?

Clayton Astles
CEO, Austco Healthcare

We haven't set a target for the number of acquisitions we want to make, but we're very active, and we're looking at a number of potential targets currently. We're looking at targets that will add value to the Austco business. Every deal has to do one of two things. It either gives us a direct access to a market where we used to sell through a reseller, for example, or it brings technology into our product portfolio that complements what we already have. Sometimes we make a build versus buy decision, and it makes more sense to buy the technology than build it. We don't really consider distressed businesses. The businesses that we've acquired so far, the four we've completed, and then RTM and CareTech, are profitable businesses, growth businesses.

On the AUD 250 million, that's certainly an aspirational target, and it'll be driven by a combination of organic growth and acquisitions of strong, complementary businesses.

Speaker 1

Is it likely that there'll be other software acquisitions in the medium term?

Clayton Astles
CEO, Austco Healthcare

We certainly hope so. There are a number of targets that we're looking at. Again, it has to fit well, but it's not just the technology. The business has to be on solid, growing, and profitable, but also it's about the culture and the teams within those organizations. That's a big part of what we do in due diligence, is making sure that there's a strong cultural fit and we're aligned that way. Thankfully, it's not by accident. The acquisitions we've completed, not only have they complemented our culture and our strategic vision, but they've added to that and had great influence on the core business.

Speaker 1

Right. Okay. In the RTM acquisition, the multiple on the earnout was about 6x, which is well above the typical 3.5x that you've referred to. I'm just wondering what differentiates RTM that justifies that much higher multiple?

Clayton Astles
CEO, Austco Healthcare

Yeah. The short answer is because RTM is a software business, and we plan to deploy the solution to our customers around the world. The 3.5x multiple for other acquisitions have delivered tremendous value for Austco. RTM is a different type of acquisition for us. It's a software business that generates recurring revenues and maintenance revenues. Its solutions are installed at more than 600 facilities across Australia, and its products are going to be rolled out globally. The other acquisitions, very strong, fantastic organizations, but they're regional services businesses, so very, very different. Even so, with the 6x multiple, we believe we're getting excellent value in a growing software business.

Speaker 1

Is there a functionality in software or in hardware where there's a gap in your portfolio at the moment?

Clayton Astles
CEO, Austco Healthcare

RTM closes a big one. With the proactive system health monitoring, what we're providing to our customers is essentially a life safety system. We're making sure that patients are getting assistance as quickly as possible by the right caregiver at the right time. For us, making sure that those systems are actively monitored 24 hours a day by our support teams, and we're proactively resolving issues before even the customer notices, that's a huge gap. There are some others we're looking at around artificial intelligence that provide clinical decision support and other AI functionality. Again, there's always a process of build versus buy. There are opportunities out there that we're exploring, and right now, it could be AI.

Speaker 1

Okay. In the lead-up to the FY 2026 result, the company referred to competition from AI demand having an impact on sourcing servers and electronic equipment. I'm wondering if that is still an issue for Austco, and if so, how are you addressing it?

Clayton Astles
CEO, Austco Healthcare

Yeah. There is a bit of that still. We have competition for memory and processors from the AI industry as the AI organizations build compute and data centers. It's placed some pressure on the availability of some of those components that we use in our products and third-party servers that we use on the backend of our products. So availability has, the lead times have stretched out. But not only that, pricing has increased. Now, we've repriced our solutions, and our customers aren't shocked. They're seeing it across the board. Their own IT departments are facing those challenges as well. We're passing along those increases, and what we hope is that we'll see some stability in the short term that help us clear that hurdle.

Speaker 1

Right. Okay. Previously, Austco had referred to double-digit organic growth. That reference wasn't there in the AGM. I'm just wondering if industry growth has slowed, given the kinds of things you've just been saying, and is that being experienced by Austco as well?

Clayton Astles
CEO, Austco Healthcare

Yeah, that's a good question. The market hasn't slowed. What we're seeing in our sales pipeline is growth and strong growth. Large hospital projects have slipped, so decision-making has slipped somewhat due to supply chain uncertainty. But demand in our market is extremely strong, so populations are aging, hospitals and aged care facilities are short on beds. None of that has changed. What's changed is timing. Large hospital projects are slipping as far as timing, funding approvals, and supply chain challenges. So those projects are deferred, not lost. And we've done a good job of managing that so far.

Speaker 1

Okay. So EBITDA margins have increased, as you highlighted in your slide deck. And I'm just wondering, can you increase those margins further from the 16% reported last year? And what do you think would be the key driver of that?

Clayton Astles
CEO, Austco Healthcare

Absolutely. EBITDA margin is one of the key metrics that we're focused on. Our EBITDA margin has grown steadily over the past few years from about 13% in FY 2024 to about 16% in FY 2026. And that's while carrying the full cost of those three acquired businesses. So we expect steady growth in EBITDA margin over time. We do plan to continue investing in growth initiatives that drive top-line growth, which will take time to translate. But a big driver of that is something we've already discussed, software and maintenance revenues will help drive, because they're higher margin by nature, that it will help drive that EBITDA margin growth.

Speaker 1

Can you increase the margin on your equipment and installation business?

Clayton Astles
CEO, Austco Healthcare

To some degree. With the supply chain challenges and the increased raw material prices and that sort of thing, it is a little bit challenging to significantly drive the increase in hardware margins, but it is something that we do incrementally year-over-year. It is not going to be as rapid of a change as we would see by growing our software and recurring revenues.

Speaker 1

Right. The final question from me, backlog revenues or UCR seem to have plateaued recently. Why is that? What should we expect from UCR levels over time?

Clayton Astles
CEO, Austco Healthcare

Yeah. The backlog is lumpy by nature, and some of it is foreign currency as well. We report in Australian dollars, but about 80% of our order book is in foreign currency, so the reported number moves with the Australian dollar. At a constant currency, UCR was actually up over the year, but it was reported, it appeared that it had fallen. New orders rose from AUD 45 million at June 30 and then to AUD 51 million in August. Up 13% over that period. It also depends on if we deliver large contracts. When you win a large contract and you deliver on that, your UCR number drops down, but then it fluctuates. It is lumpy by nature, but also some of that is related to a delay in making decisions. We have continued to grow while the UCR number is marginally higher.

As those decisions are made, we expect to see that UCR number continue to grow.

Speaker 1

Right. So do you think there is capacity for a step change, or is it naturally going to be just sort of a bit of a spillover in revenue that hasn't actually made it into a particular financial period?

Clayton Astles
CEO, Austco Healthcare

Absolutely. You may not recall, but a few years ago, our UCR number was steady at around AUD 30 million, and then there was a step change where it jumped to AUD 50 million, and that happens. So yeah, absolutely. That's what we count on, and monitoring our sales pipeline, all the indicators are there that we expect a step change in the UCR number.

Speaker 1

Right. Okay. Well, thank you very much, Clayton. That's all we've got time for. So thank you for sharing your time and your insights with us today. We'll take a short break and be back with 4DMedical and John Hester.

Clayton Astles
CEO, Austco Healthcare

Thank you for having me.